NI201700072A - Compuestos para tratar el cáncer. - Google Patents

Compuestos para tratar el cáncer.

Info

Publication number
NI201700072A
NI201700072A NI201700072A NI201700072A NI201700072A NI 201700072 A NI201700072 A NI 201700072A NI 201700072 A NI201700072 A NI 201700072A NI 201700072 A NI201700072 A NI 201700072A NI 201700072 A NI201700072 A NI 201700072A
Authority
NI
Nicaragua
Prior art keywords
compounds
treat cancer
mps
prophylaxis
diseases
Prior art date
Application number
NI201700072A
Other languages
English (en)
Inventor
Schulze Volker
Lerchen Hans-Georg
Lücking Ulrich
Wengner Antje
Siemeister Gerhard
Lienau Philip
Krenz Ursula
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of NI201700072A publication Critical patent/NI201700072A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Derivados profármacos de inhibidores de la quinasa Mps-1 y su uso en el tratamiento y/o la profilaxis de enfermedades.
NI201700072A 2014-12-09 2017-06-09 Compuestos para tratar el cáncer. NI201700072A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196859 2014-12-09

Publications (1)

Publication Number Publication Date
NI201700072A true NI201700072A (es) 2017-07-17

Family

ID=52011093

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201700072A NI201700072A (es) 2014-12-09 2017-06-09 Compuestos para tratar el cáncer.

Country Status (27)

Country Link
US (1) US20170342064A1 (es)
EP (1) EP3230285A1 (es)
JP (1) JP2017537116A (es)
KR (1) KR20170088872A (es)
CN (1) CN107001376A (es)
AR (1) AR102947A1 (es)
AU (1) AU2015359593A1 (es)
BR (1) BR112017012317A2 (es)
CA (1) CA2969902A1 (es)
CO (1) CO2017005741A2 (es)
CR (1) CR20170243A (es)
CU (1) CU20170078A7 (es)
DO (1) DOP2017000136A (es)
EA (1) EA201791264A1 (es)
EC (1) ECSP17036251A (es)
IL (1) IL252237A0 (es)
MA (1) MA41136A (es)
MX (1) MX2017007655A (es)
NI (1) NI201700072A (es)
PE (1) PE20170927A1 (es)
PH (1) PH12017501063A1 (es)
SG (1) SG11201704684PA (es)
TN (1) TN2017000241A1 (es)
TW (1) TW201625565A (es)
UY (1) UY36421A (es)
WO (1) WO2016091825A1 (es)
ZA (1) ZA201704589B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080107408A (ko) * 2006-03-07 2008-12-10 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2014198647A2 (en) * 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines

Also Published As

Publication number Publication date
CA2969902A1 (en) 2016-06-16
CU20170078A7 (es) 2017-10-05
PE20170927A1 (es) 2017-07-13
TW201625565A (zh) 2016-07-16
ZA201704589B (en) 2019-02-27
AU2015359593A1 (en) 2017-06-08
PH12017501063A1 (en) 2017-12-11
MX2017007655A (es) 2017-10-11
EA201791264A1 (ru) 2017-12-29
CO2017005741A2 (es) 2017-08-31
SG11201704684PA (en) 2017-07-28
CN107001376A (zh) 2017-08-01
UY36421A (es) 2016-06-30
KR20170088872A (ko) 2017-08-02
MA41136A (fr) 2017-10-17
WO2016091825A1 (en) 2016-06-16
CR20170243A (es) 2017-07-26
IL252237A0 (en) 2017-07-31
DOP2017000136A (es) 2017-08-31
JP2017537116A (ja) 2017-12-14
AR102947A1 (es) 2017-04-05
US20170342064A1 (en) 2017-11-30
TN2017000241A1 (en) 2018-10-19
ECSP17036251A (es) 2017-06-30
EP3230285A1 (en) 2017-10-18
BR112017012317A2 (pt) 2018-04-24

Similar Documents

Publication Publication Date Title
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016002514A1 (es) Uso de dianhidrogalactilol y análogos o derivados del mismo para tratar células no pequeñas de carcinoma de pulmón y cáncer de ovarios
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
NZ724691A (en) Quinoline derivatives as smo inhibitors
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
ES2968042T3 (es) Uso de DREADD para la modulación neuronal en el tratamiento de enfermedades neuronales
EP3148526A4 (en) Use of eribulin in the treatment of cancer
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CU20150176A7 (es) Derivados de prodroga de triazolpiridinas sustituídas
ES2759940T8 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
NI201700072A (es) Compuestos para tratar el cáncer.
CL2018001871A1 (es) Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario